John Theurer to host 9th annual neuro-oncology symposium on May 17

NewsGuard 100/100 Score

John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will host its Ninth Annual Neuro-Oncology Symposium on Friday, May 17th from 8:00am-1:00pm. Experts from MD Anderson, Memorial Sloan Kettering Cancer Center, Penn State Milton S. Hershey Medical Center, and the Cleveland Clinic will present advances in multidisciplinary care for cancers of the central nervous system.

"Our guest speakers are among the nation's leaders in neuro-oncology," said Samuel Goldlust, M.D., Co-Chief of the Brain and Spine Institute at John Theurer Cancer Center. "They will present their perspectives on the latest neurosurgical and medical treatment options and those on the horizon."

This program is intended for all healthcare providers who care for patients with central nervous system (CNS) cancers. At the conclusion of the program participants will be able to identify current standards of care, describe benchmark data that led to current treatment paradigms, and review recent advances in multidisciplinary care and the potential impact on survival and quality of life.

"This is an opportunity for healthcare professionals in the tristate area involved in the treatment of CNS cancers to learn about advances in research that shape the way we care for patients. " said George Kaptain, M.D., Co-Chief of the Brain and Spine Institute.

Featured speakers and their presentations include:

  • John DeGroot, M.D., Associate Professor, Department of Neuro-Oncology, University of Texas, M.D. Anderson Cancer Center: Anti-Angiogenic Therapy: Efficacy and Mechanisms of Resistance
  • Michael J. Glantz, M.D., Professor Neurosurgery, Medicine and Neurology, Penn State Milton S. Hershey Medical Center: Neoplastic Meningitis: How Can We Stop Snatching Defeat From The Jaws of Victory?
  • Jason T. Huse, M.D., Ph.D., Assistant Attending, Department of Pathology, Memorial Sloan-Kettering Cancer Center: The Emerging Molecular Foundations of Diffuse Gliomas
  • Michael Vogelbaum, M.D., Ph.D., Associate Director, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation: Surgery for Gliomas: How Far Should We Go?

"It's an exciting time for neuro-oncology at our Brain and Spine Institute," said Chief Emeritus Mark S. Pascal, M.D. "Recently we have seen tremendous programmatic growth, including in our Gamma Knife radiosurgery center, robust clinical trial program, and dedicated support services for neuro-oncology patients."

The conference will be held at John Theurer Cancer Center, 92 Second Street, Hackensack, NJ 07601. HackensackUMC designates this educational activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)-, physicians should only claim credits commensurate with the extent of their participation in the activity. This conference is complimentary but advanced registration is required. To register or for more information, please contact Maryann V. Lederhilger at 551-996-1162 or [email protected].

"Oncology is moving at an accelerated pace," said Andre Goy, M.D., M.S., Chairman and Director, Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation at Regional Cancer Care Associates. "We believe it is more important than ever to help physicians and healthcare professional stay up to date with the latest research and treatment best practices."

"John Theurer Cancer Center is committed to helping healthcare professionals gain access to, and knowledge of, the latest advancements in cancer care, and we are proud to offer continuing education programs like the neuro-oncology symposium to help fulfill this goal," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor, and Vice President of Cancer Services and President of Regional Cancer Care Associates.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Largest study of BRCA1 and BRCA2 carriers refines cancer risk estimates in Asian population